John Floyd

518 total citations
39 papers, 307 citations indexed

About

John Floyd is a scholar working on Genetics, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John Floyd has authored 39 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 15 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John Floyd's work include Glioma Diagnosis and Treatment (16 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Brain Metastases and Treatment (9 papers). John Floyd is often cited by papers focused on Glioma Diagnosis and Treatment (16 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Brain Metastases and Treatment (9 papers). John Floyd collaborates with scholars based in United States and Greece. John Floyd's co-authors include Andrew Brenner, Joel Michalek, Elizabeth D. Euscher, Ian E. McCutcheon, Eudocia Q. Lee, David J. Wallace, David A. Reardon, Shi‐Liang Huang, Patrick Y. Wen and Jesse S. Rodriguez and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

John Floyd

37 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Floyd United States 12 89 76 74 55 47 39 307
Erell Guillerm France 9 82 0.9× 68 0.9× 102 1.4× 114 2.1× 38 0.8× 21 351
Katarzyna Elandt Austria 10 127 1.4× 121 1.6× 71 1.0× 135 2.5× 44 0.9× 23 379
Dror Limon Israel 11 162 1.8× 166 2.2× 147 2.0× 45 0.8× 36 0.8× 45 395
Wajeeha Razaq United States 9 37 0.4× 77 1.0× 104 1.4× 69 1.3× 29 0.6× 20 269
Kenneth Bastin United States 10 64 0.7× 111 1.5× 62 0.8× 66 1.2× 58 1.2× 15 318
M Slavík Czechia 11 125 1.4× 191 2.5× 102 1.4× 84 1.5× 61 1.3× 50 439
Sweta Sudhir United States 8 64 0.7× 48 0.6× 99 1.3× 134 2.4× 13 0.3× 16 373
Shinobu Yamada Japan 8 53 0.6× 45 0.6× 85 1.1× 67 1.2× 16 0.3× 25 240
Julian Mangesius Austria 9 51 0.6× 88 1.2× 84 1.1× 89 1.6× 78 1.7× 23 287
Joseph W. Po Australia 12 72 0.8× 60 0.8× 155 2.1× 112 2.0× 21 0.4× 15 320

Countries citing papers authored by John Floyd

Since Specialization
Citations

This map shows the geographic impact of John Floyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Floyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Floyd more than expected).

Fields of papers citing papers by John Floyd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Floyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Floyd. The network helps show where John Floyd may publish in the future.

Co-authorship network of co-authors of John Floyd

This figure shows the co-authorship network connecting the top 25 collaborators of John Floyd. A scholar is included among the top collaborators of John Floyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Floyd. John Floyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brenner, Andrew, Toral Patel, Ande Bao, et al.. (2025). Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial. Nature Communications. 16(1). 2079–2079. 7 indexed citations
2.
Kelly, William, Virginia Kaklamani, Kate Lathrop, et al.. (2024). Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial. Nature Communications. 15(1). 6707–6707. 12 indexed citations
3.
4.
Kelly, William, Andrea Gilbert, Joel Michalek, et al.. (2023). CTNI-10. SACITUZUMAB GOVITECAN FOR BREAST CANCER BRAIN METASTASIS. Neuro-Oncology. 25(Supplement_5). v75–v75. 1 indexed citations
5.
Brenner, Andrew, Toral Patel, Michael Youssef, et al.. (2023). TIPS-23 SAFETY AND FEASIBILITY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN RECURRENT GLIOMA: THE RESPECT-GBM TRIAL. Neuro-Oncology Advances. 5(Supplement_3). iii39–iii39. 1 indexed citations
6.
Youssef, Michael, Ande Bao, William T. Phillips, et al.. (2023). LMAP-21 PRELIMINARY CLINICAL DATA IN THE PHASE 1/2A DOSE ESCALATION TRIAL OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN LEPTOMENINGEAL METASTASES (LM): THE RESPECT-LM TRIAL. Neuro-Oncology Advances. 5(Supplement_3). iii14–iii14. 4 indexed citations
7.
Brenner, Andrew, Joel Michalek, Melissa M. Moore, et al.. (2023). CTNI-50. UPDATE REPORT OF THE RESPECT-GBM PHASE I/IIA DOSE ESCALATION TRIAL OF RHENIUM-186 NANOLIPOSOME (186RNL) IN RECURRENT GLIOMA [RGBM] VIA CONVECTION ENHANCED DELIVERY (CED). Neuro-Oncology. 25(Supplement_5). v86–v86. 1 indexed citations
8.
Brenner, Andrew, Michael Youssef, Norman LaFrance, et al.. (2022). LOCL-04 SAFETY AND FEASIBILITY OF RHENIUM-186 NANOLIPOSOME (186RNL) IN LEPTOMENINGEAL METASTASES [LM] PHASE 1/2A DOSE ESCALATION TRIAL. Neuro-Oncology Advances. 4(Supplement_1). i12–i12. 1 indexed citations
9.
Huang, Shi‐Liang, Joel Michalek, David A. Reardon, et al.. (2021). Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET. Scientific Reports. 11(1). 7632–7632. 20 indexed citations
10.
Brenner, Andrew, Renu Pandey, John Floyd, et al.. (2021). Abstract PD13-05: Delivery and activity of SN-38 by sacituzumab govitecan in breast cancer brain metastases. Cancer Research. 81(4_Supplement). PD13–5. 14 indexed citations
11.
Gilbert, Andrea, et al.. (2020). Lost to Follow-Up: Complications of an Invasive Giant Prolactinoma. Cureus. 12(8). e9763–e9763. 1 indexed citations
12.
Fletcher-Sananikone, Eliot, Bipasha Mukherjee, Rahul K. Kollipara, et al.. (2019). Radiation-Induced DNA Damage Cooperates with Heterozygosity of TP53 and PTEN to Generate High-Grade Gliomas. Cancer Research. 79(14). 3749–3761. 24 indexed citations
13.
Wallace, David J., et al.. (2018). Bone flap salvage in acute surgical site infection after craniotomy for tumor resection. Neurosurgical Review. 41(4). 1071–1077. 19 indexed citations
14.
Fountzilas, Christos, Katherine Chang, Joel Michalek, et al.. (2017). Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experience. Journal of Gastrointestinal Oncology. 8(1). 55–63. 13 indexed citations
15.
Floyd, John, et al.. (2017). Implant compositions for the unidirectional delivery of drugs to the brain. Drug Development and Industrial Pharmacy. 43(9). 1421–1429. 6 indexed citations
16.
Gruslova, Aleksandra, David Cavazos, Jessica R. Miller, et al.. (2015). VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme. Journal of Neuro-Oncology. 124(3). 365–372. 19 indexed citations
17.
Brenner, Andrew, et al.. (2015). Osteolytic calvarial lesions as initial presentation of latent neurosyphilis. Journal of Clinical Neuroscience. 22(5). 909–910. 3 indexed citations
18.
Fan, Hongxin, et al.. (2015). Primary Central Nervous System Histiocytic Sarcoma Arising After Precursor B-Cell Acute Lymphoblastic Leukemia. Journal of Neuropathology & Experimental Neurology. 74(12). 1120–1126. 11 indexed citations
19.
Chang, Katherine W., Brian Hernandez, Joel Michalek, et al.. (2015). Clinical prognostic characteristics in predicting brain metastasis in patients with colorectal cancer: A single institution analysis.. Journal of Clinical Oncology. 33(15_suppl). e14640–e14640. 1 indexed citations
20.
Brenner, Andrew, Jessica D. Sun, John Floyd, et al.. (2014). Phase 1/2 study of investigational hypoxia-targeted drug, TH-302, and bevacizumab (bev) in recurrent glioblastoma (GBM) following bev failure.. Journal of Clinical Oncology. 32(15_suppl). 2029–2029. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erell Guillerm Breakdown of academic impact, for papers by Katarzyna Elandt Breakdown of academic impact, for papers by Dror Limon Breakdown of academic impact, for papers by Wajeeha Razaq Breakdown of academic impact, for papers by Kenneth Bastin Breakdown of academic impact, for papers by M Slavík Breakdown of academic impact, for papers by Sweta Sudhir Breakdown of academic impact, for papers by Shinobu Yamada Breakdown of academic impact, for papers by Julian Mangesius Breakdown of academic impact, for papers by Joseph W. Po
Rankless by CCL
2026